<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576887</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1201</org_study_id>
    <secondary_id>2012-001563-78</secondary_id>
    <nct_id>NCT01576887</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a multi-center, double-blinded, randomized, study of bardoxolone methyl
      treatment in patients with End-Stage Renal Disease (ERSD) and Type 2 Diabetes Mellitus (T2DM)
      on peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IDMC recommendation for safety concerns
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Approximately 17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of Adverse Events</measure>
    <time_frame>Approximately 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Residual Renal Function</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180, 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180, 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>2, 4, 8, 24 hours, 30, 60, 90, 120, 150 and 180 days</time_frame>
    <description>Only the first 8 patients randomized will have the PK drawn and hours 2, 4, 8, and 24. All patients will have the PK drawn at 30, 60, 90, 120, 150 and 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>2, 4, 8 and 24 hours</time_frame>
    <description>Only the first 8 patients randomized</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone Methyl 20 mg</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have ESRD and been on PD for longer than 3 months

          2. Patients must have had a diagnosis of T2DM prior to starting dialysis

          3. Patients must have RRF, as defined by the mean of urea and creatinine clearance on a
             24 hour urine collection, ≥ 25 Liters/week/1.73 m2 documented in the four months prior
             to the Screen A visit

          4. Patients must have RRF, as defined by the mean of urea and creatinine clearances on a
             24 hour urine collection, ≥ 25 Liters/week/1.73 m2 at both the Screen A and Screen B
             visits

          5. The RRF value obtained at the Screen B visit, must not be less than 50% of the RRF
             value obtained at the Screen A visit

          6. Patients must be at least 18 years of age

          7. Patients must have a mean systolic blood pressure (SBP) on three readings at both
             Screen A and Screen B visits ≤ 160 mmHg and ≥ 90 mmHg

          8. Patients must have a mean diastolic blood pressure (DBP) on three readings at both
             Screen A and Screen B visits &lt; 100 mmHg and ≥ 40 mmHg

          9. Patients must be willing to practice methods of birth control (both males who have
             partners of childbearing potential and females of childbearing potential) during
             screening, while taking study drug and for at least 30 days after the last dose of
             study drug is ingested

         10. Patients must be willing and able to cooperate with all aspects of the protocol

         11. Patients must be willing and able to give written informed consent to participate in
             the study. They must provide consent for access to medical data according to
             appropriate local data protection legislation and allow authorization to access
             medical records that describe events captured in the endpoints

        Exclusion Criteria:

          1. History of Autosomal Dominant Polycystic Kidney Disease

          2. Currently Active Systemic Lupus Erythematosus

          3. History of Hepatitis B Surface Antigen +

          4. History of Hepatitis C Antibody + being treated with antiviral therapy

          5. History of an organ transplant

          6. A planned renal transplant from a living donor during the study

          7. History of hospitalization for congestive heart failure or pulmonary edema within 12
             weeks before study randomization

          8. History of cirrhosis of the liver

          9. History of amyloidosis or light chain nephropathy

         10. History of hemoglobin A1c level &gt; 11.0% (97 mmol/mol) within 12 weeks before study
             randomization

         11. History of recently active cardiovascular disease defined as:

               1. Unstable angina pectoris within 12 weeks before study randomization

               2. Myocardial infarction, coronary artery bypass graft surgery, or percutaneous
                  transluminal coronary angioplasty/stent within 12 weeks before study
                  randomization

               3. Cerebrovascular accident, including transient ischemic attack within 12 weeks
                  before study randomization

         12. History of a diagnostic or interventional procedure that required intravenous
             administration of an iodinated contrast agent or gadolinium within 12 weeks before
             study randomization

         13. History of known severe obstructive valvular heart disease or severe obstructive
             hypertrophic cardiomyopathy

         14. History of known 2o or 3o atrioventricular block not successfully treated with a
             pacemaker

         15. History or resuscitated sudden cardiac death

         16. History of an automatic implantable defibrillator

         17. QTc greater than 0.50 seconds on an ECG obtained during either Screen A or Screen B
             visits

         18. A serum magnesium level less than 1.4 meq/L on either Screen A or Screen B visit
             laboratory test results

         19. History of systemic immunosuppression for more than 15 days, cumulatively, within the
             12 weeks prior to study randomization or anticipated need for more than 15 days of
             immunosuppression during the study

         20. Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level
             greater than the upper limit of normal (ULN) or alkaline phosphatase level greater
             than two times the ULN on either the Screen A and Screen B visit laboratory test
             results

         21. Known hypersensitivity to any component of the study drug

         22. Current history of drug or alcohol abuse, as assessed by the investigator

         23. History of clinically significant infection requiring intravenous administration of
             antibiotics or hospitalization within 12 weeks before study randomization

         24. In patients who have been on peritoneal dialysis for ≥ 6 months, two or more episodes
             of peritonitis in the 6 months before study randomization. In patients who have been
             on peritoneal dialysis for &lt;6 months, one episode of peritonitis before study
             randomization

         25. History of a diagnosis or treatment of a malignancy in the past 5 years, excluding
             non-melanoma skin cancer and carcinoma in situ of the cervix

         26. History of a clinical condition that, in the judgment of the investigator, could
             potentially pose a health risk to the patient while involved in the study

         27. Patient is unable to communicate or cooperate with the investigator due to language
             problems, poor mental development, or impaired cerebral function

         28. Participation in a clinical study involving any intervention within 30 days prior to
             Screen A visit, concurrent participation in such a study, or participation in a prior
             clinical study involving bardoxolone methyl in any form

         29. Female patients who are pregnant, intend to become pregnant during this study, or are
             nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

